Vabysmo – Talk Bio

Roche in Talks With US on Drug Pricing; Sets Out Pipeline and Dealmaking Ambitions

4 days ago talkbio0Tagged Benefit, dealmaking, direct-to-consumer sales, drug price, gene therapy, Government, Hemlibra, Investments, manager, Manufacturing, Ocrevus, Pharmaceutical Services, pipeline, R&D, Roche (company), U.S., Vabysmo

Roche; drug pricing; US government; pharmacy benefit managers; direct-to-consumer sales; pipeline; dealmaking; US investment; manufacturing; gene therapy; R&D; Ocrevus; Hemlibra; Vabysmo

Ollin Biosciences Launches with $100M to Challenge Roche in Eye Disease Market

1 month ago talkbio0Tagged Ang2, Biosciences, Clinical Trials, Disorder of eye, Macular edema due to diabetes mellitus, Ollin, OLN324, Roche (company), Vabysmo, Vascular Endothelial Growth Factor A, Wet AMD

Ollin Biosciences; Roche; eye disease; biotech; VEGF-A; Ang2; wet AMD; diabetic macular edema; clinical trial; OLN324; Vabysmo

Roche Pledges Nearly $300M to Establish New Vabysmo Production Plant in China

6 months ago talkbio0Tagged Biopharmaceutical manufacturing, China, Disorder of eye, green energy, Investments, localization, plant construction, Roche (company), Shanghai, Vabysmo

Roche; Vabysmo; biopharmaceutical manufacturing; Shanghai; China; investment; eye disease treatment; plant construction; localization; green energy

Vabysmo’s Growth Pace Slows in Q3, Still on Track for Dominance in Eye Disease Market

1 year ago talkbio0Tagged Age related macular degeneration, Macular edema due to diabetes mellitus, Market, Regeneron, Roche (company), Vabysmo, Vascular Endothelial Growth Factor A

Vabysmo, Roche, Regeneron, Eylea HD, eye disease market, vascular endothelial growth factor A (VEGF-A) therapy, age-related macular degeneration (AMD), diabetic macular edema (DME).